{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:53:28Z","timestamp":1791604408054,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>With an additional year of follow\u2010up compared with the previous report, this study presents the 27.2\u2010month efficacy and safety outcomes of the MajesTEC\u20101 China cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 26 participants with triple\u2011class exposed relapsed\/refractory multiple myeloma (TCE\u2010RRMM) received subcutaneous teclistamab 1.5\u00a0mg\/kg weekly, with potential transition to every 2 weeks in sustained responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall response rate (ORR) was 76.9%, with all responders achieving a very good partial response or better (\u2265 VGPR), and 75% achieving a complete response or better (\u2265 CR). Median progression\u2011free survival (PFS) was 25.1 months, while median duration of response (DOR) and overall survival (OS) were not reached. Among patients achieving \u2265 CR, estimated 30\u2011month DOR, PFS, and OS rates were favorable at 80.0%, 80.0%, and 93.3%, respectively. Patients with poor prognostic features achieved ORRs comparable to overall population, and their DOR was generally consistent. Quality\u2010of\u2010life assessments showed improvements from baseline in global health status, physical functioning, fatigue, and pain. Safety profile was consistent with previous publication. Incidence of new\u2010onset Grade \u2265 3 infections decreased over time, which was consistent with the timing of transition to biweekly dosing and may be related to immunoglobulin use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings support teclistamab as a standard\u2010of\u2010care for patients with TCE\u2010RRMM in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT03145181\/NCT04557098<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70340","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:56:11Z","timestamp":1785423371000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Teclistamab in Relapsed\/Refractory Multiple Myeloma: 2\u2010Year Follow\u2010Up From MajesTEC\u20101 China Cohort"],"prefix":"10.1002","volume":"7","author":[{"given":"Zhen","family":"Cai","sequence":"first","affiliation":[{"name":"First Affiliated Hospital Zhejiang University College of Medicine Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Xi'an Jiaotong University  Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Dong","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[{"name":"Shengjing Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Chen","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Zuppa","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan  New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan  New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latisha","family":"Watkins","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan  New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchao","family":"Luo","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Xu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wannan","family":"Chen","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeline","family":"Zhu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Fu","sequence":"additional","affiliation":[{"name":"Shanghai Changzheng Hospital Naval Medical University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[{"name":"West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Shanghai Changzheng Hospital Naval Medical University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70442\u20105"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217440"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-403733"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-740944"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201010\u2010116129"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001531\u20102"},{"key":"e_1_2_12_10_1","unstructured":"National Medical Products Administration \"Ciltacabtagene Autoleucel Injection Approved for Marketing by China NMPA \"2025 https:\/\/english.nmpa.gov.cn\/2025\u201002\/19\/c_1073597.htm."},{"key":"e_1_2_12_11_1","unstructured":"National Medical Products Administration \"Equecabtagene Autoleucel Injection Approved With Conditions by China NMPA \"2023 https:\/\/english.nmpa.gov.cn\/2023\u201006\/30\/c_940315.htm."},{"key":"e_1_2_12_12_1","unstructured":"Antengene Corporation \u201cAntengene Announces NDA Approval by NMPA for XPOVIO\u00ae China's First XPO1 Inhibitor for the Treatment of Adults With Relapsed or Refractory Multiple Myeloma \u201d2021 Accessed February 13 2026 https:\/\/www.antengene.com\/newsinfo\/65#:~:text=Antengene%20Corporation%20Limited%20%28the%20%E2%80%9CCompany%E2%80%9D%20or%20%E2%80%9CAntengene%E2%80%9D%29%20is an%20immunomodulatory%20agent%20and%20an%20anti."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010022\u201002305\u20104"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010019\u20100807\u20105"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13717"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35665"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01338\u20106"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_12_23_1","unstructured":"\"EORTC QLQ\u2010C30 Scoring Manual \"European Organisation for Research and Treatment of Cancer accessed February 2026 https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.05.008"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001297\u20107"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.11.001"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1991-4"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1429"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011658"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(24)00043\u20103"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010025\u201001149\u20101"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8067"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70115"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70340","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:43:28Z","timestamp":1791603808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/jha2.70340"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70340","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"2026-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70340"}}